Zolbetuximab as a gastric lineage-directed immunotherapy: mechanistic rationale and translational evidence in CLDN18.2-positive gastroesophageal adenocarcinoma

Key Points

• The study aims to explore zolbetuximab's efficacy as a targeted treatment in specific cancer types.
• Investigated zolbetuximab as a targeted cytolytic antibody.
• Outlined future studies involving combinations with checkpoint blockade.
• Focused on refining biomarkers related to the therapy.
• Zolbetuximab shows potential as a novel treatment method.
• Recommendations for further testing combinations with existing therapies.
• Emphasis on understanding resistance mechanisms for better outcomes.